Sunesis Pharmaceuticals (SNSS) Investor Presentation - Slideshow

Pharmaceuticals, Inc. Corporate Overview December 2019 Inspired to Make a Difference for Cancer Patients Safe Harbor Statement This presentation contains forward-looking statements, including statements related to the continued development of vecabrutinib (SNS-062) and other product candidates, including the timing and preliminary results of Phase 1b/2 trial of vecabrutinib and the therapeutic potential of vecabrutinib, further development and potential of its kinase inhibitor pipeline, planned development ...